In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases.
We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following disease progression, the importance of understanding disease biology, and the nuances of NCCN guidelines.
Key topics included:
• The role of TKI options like Axitinib, Cabozantinib, and Tivozanib in second-line treatment
• The impact of disease progression on treatment decisions
• Side effect management and the importance of palliative care
• The potential use of HIF-2 alpha inhibitors like Belzutifan in specific scenarios
Join us for an informative discussion that emphasized patient-centered care and the significance of shared decision-making in oncology.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
If you enjoy our conversations, please leave us a review and let us know what topics you'd like us to cover in future episodes! Stay tuned for more insights into the rapidly evolving field of cancer treatment. We are the Oncology Brothers!
#RCC #KidneyCancer #TKI #Immunotherapy #OncologyBrothers #GUOncology
